Somatostatin Receptor Theranostics for Refractory Meningiomas

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Aug 25

PMID 36005176

Authors

Betty Salgues

Thomas Graillon

Tatiana Horowitz

Olivier Chinot

Laetitia Padovani

David Taieb

Eric Guedj

Affiliations

Soon will be listed here.

Abstract

Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy. The aim of this study was to provide outcomes of patients harboring refractory meningiomas treated by 177Lu-DOTATATE and an overall analysis of progression-free survival at 6 months (PFS-6) of the same relevant studies in the literature. Eight patients with recurrent and progressive WHO grade II meningiomas were treated after multimodal pretreatment with 177Lu-DOTATATE between 2019 and 2022. Primary and secondarily endpoints were progression-free survival at 6-months (PFS-6) and toxicity, respectively. PFS-6 analysis of our case series was compared with other similar relevant studies that included 86 patients treated with either 177Lu-DOTATATE or 90Y-DOTATOC. Our retrospective study showed a PFS-6 of 85.7% for WHO grade II progressive refractory meningiomas. Treatment was clinically and biologically well tolerated. The overall analysis of the previous relevant studies showed a PFS-6 of 89.7% for WHO grade I meningiomas ( = 29); 57.1% for WHO grade II ( = 21); and 0 % for WHO grade III ( = 12). For all grades ( = 86), including unknown grades, PFS-6 was 58.1%. SSTR-targeted PRRT allowed us to achieve prolonged PFS-6 in patients with WHO grade I and II progressive refractory meningiomas, except the most aggressive WHO grade II tumors. Large scale randomized trials are warranted for the better integration of PRRT in the treatment of refractory meningioma into clinical practice guidelines.

Citing Articles

A Diagnosis of Pulmonary Metastases of Benign Meningioma Using Radial Endobronchial Ultrasound.

Mencia Diez F, Egurrola Izquierdo M, Garcia Hontoria P Open Respir Arch. 2024; 7(1):100364.

PMID: 39493969 PMC: 11526065. DOI: 10.1016/j.opresp.2024.100364.

Do we need dosimetry for the optimization of theranostics in CNS tumors?.

Cicone F, Gnesin S, Santo G, Stokke C, Bartolomei M, Cascini G Neuro Oncol. 2024; 26(Supplement_9):S242-S258.

PMID: 39351795 PMC: 11631076. DOI: 10.1093/neuonc/noae200.

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up.

Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D J Nucl Med. 2024; 65(9):1409-1415.

PMID: 39142827 PMC: 11372258. DOI: 10.2967/jnumed.123.266956.

Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.

Soni N, Ora M, Bathla G, Szekeres D, Desai A, Pillai J AJNR Am J Neuroradiol. 2024; 46(2):240-250.

PMID: 38844366 PMC: 11878982. DOI: 10.3174/ajnr.A8368.

Radioligand therapies in meningioma: Evidence and future directions.

Mair M, Tabouret E, Johnson D, Sulman E, Wen P, Preusser M Neuro Oncol. 2024; 26(Supplement_9):S215-S228.

PMID: 38702966 PMC: 11631075. DOI: 10.1093/neuonc/noae069.

References

Goldbrunner R, Minniti G, Preusser M, Jenkinson M, Sallabanda K, Houdart E . EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016; 17(9):e383-91. DOI: 10.1016/S1470-2045(16)30321-7. View

Salgues B, Graillon T, Guedj E . [Ga]Ga-DOTA-TOC PET/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants. Eur J Nucl Med Mol Imaging. 2020; 48(1):316-317. DOI: 10.1007/s00259-020-04894-9. View

Garzon-Muvdi T, Bailey D, Pernik M, Pan E . Basis for Immunotherapy for Treatment of Meningiomas. Front Neurol. 2020; 11:945. PMC: 7483661. DOI: 10.3389/fneur.2020.00945. View

Cullinane C, Waldeck K, Kirby L, Rogers B, Eu P, Tothill R . Enhancing the anti-tumour activity of Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. Sci Rep. 2020; 10(1):10196. PMC: 7311440. DOI: 10.1038/s41598-020-67199-9. View

Ros-Sanjuan A, Iglesias-Morono S, Carrasco-Brenes A, Bautista-Ojeda D, Arraez-Sanchez M . Atypical Meningiomas: Histologic and Clinical Factors Associated With Recurrence. World Neurosurg. 2019; 125:e248-e256. DOI: 10.1016/j.wneu.2019.01.056. View

Bartolomei M, Bodei L, De Cicco C, Grana C, Cremonesi M, Botteri E . Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009; 36(9):1407-16. DOI: 10.1007/s00259-009-1115-z. View

Graillon T, Ferrer L, Siffre J, Sanson M, Peyre M, Peyriere H . Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study. Neuro Oncol. 2021; 23(7):1139-1147. PMC: 8661407. DOI: 10.1093/neuonc/noab019. View

Graillon T, Tabouret E, Chinot O . Chemotherapy and targeted therapies for meningiomas: what is the evidence?. Curr Opin Neurol. 2021; 34(6):857-867. DOI: 10.1097/WCO.0000000000001002. View

Hartrampf P, Hanscheid H, Kertels O, Schirbel A, Kreissl M, Flentje M . Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol. 2020; 22:29-32. PMC: 7075763. DOI: 10.1016/j.ctro.2020.03.002. View

10.

Simpson D . The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20(1):22-39. PMC: 497230. DOI: 10.1136/jnnp.20.1.22. View

11.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E . Radiation induces up-regulation of somatostatin receptors 1, 2, and 5 in small cell lung cancer in vitro also at low absorbed doses. Cancer Biother Radiopharm. 2011; 26(6):759-65. DOI: 10.1089/cbr.2010.0921. View

12.

Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E . Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006; 33(7):841-6. DOI: 10.1016/j.nucmedbio.2006.07.010. View

13.

Claringbold P, Brayshaw P, Price R, Turner J . Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010; 38(2):302-11. DOI: 10.1007/s00259-010-1631-x. View

14.

Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J . Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014; 16(6):829-40. PMC: 4022224. DOI: 10.1093/neuonc/not330. View

15.

Muther M, Roll W, Brokinkel B, Zinnhardt B, Sporns P, Seifert R . Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. Nuklearmedizin. 2020; 59(5):348-355. DOI: 10.1055/a-1200-0989. View

16.

Galldiks N, Albert N, Sommerauer M, Grosu A, Ganswindt U, Law I . PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol. 2017; 19(12):1576-1587. PMC: 5716194. DOI: 10.1093/neuonc/nox112. View

17.

ODonoghue J, Bardies M, Wheldon T . Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med. 1995; 36(10):1902-9. View

18.

Parghane R, Ostwal V, Ramaswamy A, Bhandare M, Chaudhari V, Talole S . Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease. Eur J Nucl Med Mol Imaging. 2020; 48(3):913-923. DOI: 10.1007/s00259-020-05004-5. View

19.

Mirian C, Duun-Henriksen A, Maier A, Pedersen M, Rehne Jensen L, Bashir A . Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. J Nucl Med. 2020; 62(4):507-513. DOI: 10.2967/jnumed.120.249607. View

20.

Rachinger W, Stoecklein V, Terpolilli N, Haug A, Ertl L, Poschl J . Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015; 56(3):347-53. DOI: 10.2967/jnumed.114.149120. View